388 related articles for article (PubMed ID: 8928943)
1. Comparison of the effects of low-molecular-weight and unfractioned heparin in horses.
Monreal L; Villatoro AJ; Monreal M; Espada Y; Anglés AM; Ruiz-Gopegui R
Am J Vet Res; 1995 Oct; 56(10):1281-5. PubMed ID: 8928943
[TBL] [Abstract][Full Text] [Related]
2. Reduction of the red blood cell mass of horses: toxic effect of heparin anticoagulant therapy.
Duncan SG; Meyers KM; Reed SM
Am J Vet Res; 1983 Dec; 44(12):2271-6. PubMed ID: 6660615
[TBL] [Abstract][Full Text] [Related]
3. Heparin-induced agglutination of erythrocytes in horses.
Moore JN; Mahaffey EA; Zboran M
Am J Vet Res; 1987 Jan; 48(1):68-71. PubMed ID: 3826844
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
5. Plasma heparin values and hemostasis in equids after subcutaneous administration of low-dose calcium heparin.
Gerhards H; Eberhardt C
Am J Vet Res; 1988 Jan; 49(1):13-8. PubMed ID: 3354959
[TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
7. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
8. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
Bendetowicz AV; Kai H; Knebel R; Caplain H; Hemker HC; Lindhout T; Béguin S
Thromb Haemost; 1994 Nov; 72(5):705-12. PubMed ID: 7900078
[TBL] [Abstract][Full Text] [Related]
9. Time-course of anti-Xa effects of calcium heparin and low-molecular-weight heparin given s.c.: insights for thrombosis prevention.
Romeo G; Salanitri G; Catania G
Drugs Exp Clin Res; 1988; 14(6):423-7. PubMed ID: 2850903
[TBL] [Abstract][Full Text] [Related]
10. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
11. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
Momi S; Nasimi M; Colucci M; Nenci GG; Gresele P
Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
[TBL] [Abstract][Full Text] [Related]
12. Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis.
Carelli G; Maffei FH; Mattar L; Ferrari IC; Thomazini-Santos IA; de Carvalho LR
Pathophysiol Haemost Thromb; 2005; 34(6):263-8. PubMed ID: 16772737
[TBL] [Abstract][Full Text] [Related]
13. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
15. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
Nimmerfall K; Mischke R
Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
[TBL] [Abstract][Full Text] [Related]
16. The effect of taurolidine on experimental thrombus formation.
Kaptanoglu L; Kucuk HF; Colak E; Kurt N; Bingul SM; Akyol H; Torlak OA; Yazici F
Eur J Pharmacol; 2008 Jan; 578(2-3):238-41. PubMed ID: 17961549
[TBL] [Abstract][Full Text] [Related]
17. Effects of unfractionated and low molecular weight heparin on platelet-induced thrombin formation time and platelet adhesion.
Basic-Micic M; Breddin HK
Semin Thromb Hemost; 1993; 19 Suppl 1():22-8. PubMed ID: 8395725
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
Akanmu AS; Nnodu OE; Giwa SO; Salako LA; Akinsete I; Adebule GT; Adekoya-Cole TO; Odunubi OO
Afr J Med Med Sci; 2004 Dec; 33(4):335-40. PubMed ID: 15977441
[TBL] [Abstract][Full Text] [Related]
19. In vitro anticoagulation monitoring of low-molecular-weight heparin.
Wang JQ; Shi XB; Yang JG; Hu DY
Chin Med J (Engl); 2009 May; 122(10):1199-202. PubMed ID: 19493471
[TBL] [Abstract][Full Text] [Related]
20. Comparison of unfractioned and low molecular weight heparin for prophylaxis of coagulopathies in 52 horses with colic: a randomised double-blind clinical trial.
Feige K; Schwarzwald CC; Bombeli T
Equine Vet J; 2003 Jul; 35(5):506-13. PubMed ID: 12875331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
